Workflow
中药Ⅲ
icon
Search documents
7月4日晚间重要公告一览
Xi Niu Cai Jing· 2025-07-04 10:28
资料显示,普利特成立于1999年10月,主营业务是高分子新材料产品及其复合材料,以及三元锂离子电 池、磷酸铁锂锂离子电池、钠离子电池及其系统等的研发、生产、销售和服务。 所属行业:基础化工–塑料–改性塑料 海通发展:上半年净利润预减60.78%–69.04% 芯动联科:上半年净利润预增144.46%-199.37% 7月4日晚,芯动联科(688582)发布2025年半年度业绩预告,预计上半年公司实现营业收入2.28亿元至 2.78亿元,同比增长66.04%-102.45%;预计归属于上市公司股东的净利润为1.38亿元至1.69亿元,同比 增长144.46%-199.37%。 资料显示,芯动联科成立于2012年7月,主营业务是高性能硅基MEMS惯性传感器的研发、测试与销 售。 所属行业:电子–半导体–模拟芯片设计 普利特:上半年净利润预增38.88%-66.65% 7月4日晚,普利特(002324)发布2025年半年度业绩预告,预计上半年公司实现归属于上市公司股东的 净利润2亿元至2.4亿元,同比增长38.88%-66.65%;预计扣除非经常性损益后的净利润为1.95亿元至2.32 亿元,同比增长49.77%- ...
7月3日晚间重要公告一览
Xi Niu Cai Jing· 2025-07-03 10:18
盛德鑫泰:中标约2.17亿元火电需用钢管项目 7月3日晚,盛德鑫泰(300881)发布公告称,公司中标"宝山、阳西、南阳等火电项目"的需用钢管,中 标金额约2.17亿元(含税),占公司2024年度经审计营业收入的8.15%。该项目采购单位为上海锅炉厂 有限公司,中标标的为S30432、HR3C高等级不锈钢。 资料显示,盛德鑫泰成立于2001年10月,主营业务是各类工业用能源设备类无缝钢管的生产、研发和销 售。 所属行业:钢铁–特钢Ⅱ–特钢Ⅲ 高铁电气:控股子公司中标7176.16万元项目 7月3日晚,高铁电气(688285)发布公告称,控股子公司宝鸡保德利电气设备有限责任公司中标新建上 海至南京至合肥高速铁路沪宁段(江苏段)项目,中标金额为7176.16万元(含税)。该项目为国铁集 团管理甲供物资(四电物资)接触网关键零部件,包含腕臂底座、腕臂装置、定位装置等。 资料显示,高铁电气成立于1989年9月,主营业务是铁路电气化接触网系统设备、城市轨道交通供电系 统设备及轨外产品的研发、设计、制造和销售。 所属行业:机械设备–轨交设备Ⅱ–轨交设备Ⅲ 藏格矿业:麻米措矿业取得建筑工程施工许可证 7月3日晚,藏格矿业( ...
7月1日晚间重要公告一览
Xi Niu Cai Jing· 2025-07-01 10:29
Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]
7月1日早间重要公告一览
Xi Niu Cai Jing· 2025-07-01 03:51
Group 1 - Kanghong Pharmaceutical received a drug registration certificate for Lifisig Eye Drops, approved for treating dry eye symptoms [1] - Kanghong Biotech, a wholly-owned subsidiary, received clinical trial approval for KH813 injection for metastatic non-squamous non-small cell lung cancer [1] - Kanghong Pharmaceutical was established in October 1996, focusing on drug and medical device research, production, and sales [1] Group 2 - Guoyuyuan's subsidiary received a government subsidy of 7.5521 million yuan, accounting for 10.14% of the company's audited net profit for 2024 [2] - Guoyuyuan was founded in November 1996, specializing in drug research, production, and sales [3] Group 3 - Haicheng Bonda's subsidiary signed a lease termination agreement, incurring a termination fee of 3.35 million USD [4] - Haicheng Bonda was established in December 2009, providing comprehensive modern logistics services [4] Group 4 - Hongxin Electronics' subsidiary signed contracts totaling 373 million yuan for computing power business [5] - Hongxin Electronics was founded in September 2003, focusing on FPC research, design, manufacturing, and sales [6] Group 5 - Tianbang Food reached a settlement agreement regarding a 1.214 billion yuan lawsuit, agreeing to repay 410 million yuan over 36 months [8] - Tianbang Food was established in September 1996, specializing in pig farming and pork processing [9] Group 6 - Daoshi Technology's controlling shareholder plans to reduce holdings by up to 1.97% of the company's shares [10] - Daoshi Technology was founded in September 2007, focusing on ceramic color glazes and related products [10] Group 7 - Jinpu Titanium is planning a major asset restructuring, leading to a stock suspension [10] - Jinpu Titanium was established in November 1989, specializing in titanium dioxide production and sales [11] Group 8 - Shenzhen Energy plans to invest 6.332 billion yuan in upgrading the Mawan Power Plant [12] - Shenzhen Energy was founded in August 1993, focusing on conventional and renewable energy development [13] Group 9 - Lihua Co. plans to reduce holdings by up to 3% of the company's shares [14] - Lihua Co. was established in June 1997, specializing in the breeding and sales of poultry [15] Group 10 - China Communications Construction Company plans to repurchase shares worth 500 million to 1 billion yuan [16] - China Communications Construction Company was founded in October 2006, focusing on infrastructure design and construction [17] Group 11 - Huatiankeji's subsidiary received a government subsidy of 80.6569 million yuan, accounting for 13.09% of the company's latest audited net profit [20] - Huatiankeji was established in December 2003, specializing in integrated circuit packaging and testing [21] Group 12 - Luxin Chuangtou plans to acquire shares in Hongke Electronics for a total of 9 million yuan [23] - Luxin Chuangtou was founded in November 1993, focusing on venture capital and industrial development [24] Group 13 - Feilong Co.'s controlling shareholder plans to reduce holdings by up to 563,250 shares [25] - Feilong Co. was established in January 2001, specializing in thermal management components for automotive and civil applications [26] Group 14 - Linglong Tire submitted an application for H-share listing on the Hong Kong Stock Exchange [27] - Linglong Tire was founded in June 1994, focusing on tire design, development, manufacturing, and sales [27] Group 15 - Saiwei Electronics plans to acquire 9.5% of its subsidiary's shares for up to 324 million yuan [28] - Saiwei Electronics was established in May 2008, focusing on MEMS chip development and semiconductor equipment [28] Group 16 - Suzhou Bank's major shareholder plans to increase holdings by no less than 400 million yuan [29] - Suzhou Bank was founded in December 2004, focusing on various banking services [29]
嘉应制药获融资买入165.27万元,不久前被立案受损股民可索赔
Sou Hu Cai Jing· 2025-06-23 14:41
雷达财经雷助吧出品 文|吴为 编|深海 同花顺数据中心显示,嘉应制药6月20日获融资买入165.27万元,占当日买入金额的10.72%,当前融资余额2.48亿元,占流通市值的8.17%,低于历 史50%分位水平。 融券方面,嘉应制药6月20日融券偿还100股,融券卖出0股,按当日收盘价计算,卖出金额0元,融券余额9.07万,低于历史40%分位水平。 综上,嘉应制药当前两融余额2.48亿元,较昨日上升0.20%,两融余额低于历史50%分位水平。 天眼查信息显示,嘉应制药成立于2003年,申能集团成员,位于广东省梅州市,是一家以从事医药制造业为主的企业。 雷达财经注意到,嘉应制药于2025年5月28日收到中国证券监督管理委员会(以下简称"中国证监会")的《立案告知书》(证监立案字0062025010 号),因公司涉嫌信息披露违法违规,根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规,中国证监会决定对公司立案。 6月20日,公司回复投资者提问时称,公司已针对被调查一事进行了自查。 对此,四川鼎众律师事务所余君律师向雷达财经表示,上市公司信披不及时、不准确给投资者造成损失的,受损投资者可依法索赔。凡 ...
6月13日晚间重要公告一览
Xi Niu Cai Jing· 2025-06-13 10:43
固德威:拟1亿–1.5亿元回购公司股份 6月13日晚,固德威(688390)发布公告称,公司计划以集中竞价方式回购股份,回购资金总额在1亿元 至1.5亿元之间,回购价格上限为53元/股,预计回购股份数量为189万股至283万股,占总股本的0.78% 至1.17%。 资料显示,固德威成立于2010年11月,主营业务是太阳能、储能等新能源电力电源设备的研发、生产和 销售,并致力于为家庭、工商业用户及地面电站提供智慧能源管理等整体解决方案。 所属行业:电力设备–光伏设备–逆变器 双良节能:中标甘肃能化庆阳2×660MW煤电项目 6月13日晚,双良节能(600481)发布公告称,公司和中建研科技股份有限公司、河南省第二建设集团 有限公司中标甘肃能化庆阳2×660MW煤电项目工程间冷塔EPC工程招标项目,预计中标总额为2.37亿 元,占公司2024年度营业收入的1.82%。 资料显示,双良节能成立于1995年10月,主营业务是节能节水系统业务及新能源系统业务。 所属行业:电力设备–光伏设备–硅料硅片 中国太保:前5月两子公司保费收入合计2271.69亿元 6月13日晚,中国太保(601601)发布公告称,1至5月,公司 ...
盘龙药业:盘龙七片优势稳固,配方颗粒或推动第二增长曲线-20250611
同花顺金融研究中心· 2025-06-11 09:48
盘龙药业(002864.SZ) 公司深度报告 公司深度报告 | 盘龙药业(002864.SZ) 2025 年 06 月 11 日 主导产品盘龙七片竞争优势突出。盘龙七片是周恩来总理曾两次亲切接 见的我国著名骨伤科专家王家成老先生所献祖传秘方,经科学研制而成。 为全国独家专利、医保甲类品种,并被评为陕西省名牌产品和"秦药"优 势中成药。2024 年 H1 在我国城市及县级公立医院骨骼肌肉系统风湿性 疾病领域中成药市场中,公司主导产品盘龙七片市场份额排名第一,市场 份额为 8.05%,市占率不断提升。销售额从 2015 年的 1.55 亿元增长至 2023 的 4.1 亿元,年复合增长率达 12.93%,2024 年 H1 盘龙七片销售额 达 2.23 亿元。该产品已构建起差异化的市场竞争壁垒,在风湿骨病治疗 领域形成独特的临床价值优势。 2025 年 06 月 11 日 中药Ⅲ行业 配方颗粒推动第二增长曲线。中药饮片业务中配方颗粒为公司的重点发 展方向。报告期内,公司中药配方颗粒业务已完成 211 个品种的备案,并 计划通过定增募投项目扩大生产规模,目标是将备案品种增至 400 个以 上。公司致力于成为陕西省第 ...
6月6日晚间重要公告一览
Xi Niu Cai Jing· 2025-06-06 10:24
6月6日晚,白云山(600332)发布公告称,分公司白云山制药总厂收到国家药品监督管理局核准签发的 他达拉非片(2.5mg、5mg)《药品注册证书》。他达拉非是一种用于治疗男性勃起功能障碍(ED)的 磷酸二酯酶5(PDE5)抑制剂。 白云山:分公司收到药品注册证书 资料显示,白云山成立于1997年9月,主营业务是中西成药、化学原料药、天然药物、生物医药、化学 原料药中间体的研发、制造与销售;西药、中药和医疗器械的批发、零售和进出口业务;大健康产品的 研发、生产与销售;医疗服务、健康管理、养生养老等健康产业投资。 所属行业:医药生物–中药Ⅱ–中药Ⅲ 华银电力:拟投资13.98亿元开发新能源发电项目 6月6日晚,华银电力(600744)发布公告称,公司拟投资建设株洲市醴陵市沩山风电场项目、郴州市桂 东县普洛风力发电项目、衡南县向阳光伏发电项目一期工程,三个项目装机规模共计230兆瓦,总投资 额约为13.98亿元。资金来源包括资本金和银行贷款。项目已取得核准(备案)证明并获取建设指标。 资料显示,华银电力成立于1993年3月,主营业务是火力发电业务,同时经营水电、风电、太阳能业务 以及电力销售业务。 福元医药:盐酸 ...
5月29日早间重要公告一览
Xi Niu Cai Jing· 2025-05-29 04:04
中国化学:控股股东获得增持资金贷款支持 太阳电缆:股东拟减持不超过3%公司股份 5月29日,太阳电缆(002300)发布公告称,公司股东福建亿力集团有限公司计划自公告披露之日起15 个交易日后的3个月内,通过集中竞价交易或大宗交易方式减持公司股份不超过2167万股,占公司总股 本的3%。减持原因为股东自身经营需要。 资料显示,太阳电缆成立于1994年7月,主营业务是电线电缆的生产、销售。 所属行业:电力设备–电网设备–线缆部件及其他 5月29日,中国化学(601117)发布公告称,公司控股股东中国化学工程集团有限公司获得中国工商银 行股份有限公司的贷款承诺,借款额度不超过5.4亿元,专项用于实施增持计划。此前,中国化学工程 于2025年4月12日宣布拟于12个月内增持公司股份,增持金额不低于3亿元,不超过6亿元。 资料显示,中国化学成立于2008年9月,主营业务是建筑工程业务、实业、现代服务业。 所属行业:建筑装饰–专业工程–化学工程 棕榈股份:因借贷纠纷提起诉讼 涉案金额超1.49亿元 5月29日,棕榈股份(002431)发布公告称,公司因与山东胜伟盐碱地科技有限公司等多家公司及个人 的借贷纠纷,向河南省郑 ...
5月26日晚间重要公告一览
Xi Niu Cai Jing· 2025-05-26 10:11
太阳能:拟1亿-2亿元回购股份用于注销 5月26日晚,太阳能(000591)发布公告称,公司拟使用自筹资金以集中竞价交易方式回购部分A股股 份,用于依法注销减少注册资本。回购资金总额不低于1亿元且不高于2亿元,回购价格不超过6.69元/ 股。 资料显示,太阳能成立于1993年4月,主营业务是光伏电站的投资运营,光伏电池、组件的研发、生产 和销售。 所属行业:公用事业–电力–光伏发电 润阳科技:拟3亿元增资上海傅利叶智能科技有限公司 5月26日晚,润阳科技(300920)发布公告称,公司拟与上海傅利叶智能科技有限公司签订《投资意向 协议》,以不超过3亿元的现金增资傅利叶,傅利叶投前估值为80亿元。 资料显示,润阳科技成立于2012年10月,主营业务是聚烯烃发泡材料的研发、生产及销售。 所属行业:基础化工–塑料–其他塑料制品 恒瑞医药:子公司SHR-4712注射液临床试验获得批准 5月26日晚,恒瑞医药(600276)发布公告称,子公司广东恒瑞医药有限公司、上海盛迪医药有限公司 收到国家药品监督管理局核准签发的SHR-4712注射液《药物临床试验批准通知书》,即将开展治疗晚 期实体瘤的临床试验。 资料显示,恒瑞医 ...